Malignant pleural effusion: from bench to bedside

Ioannis Psallidas, Ioannis Kalomenidis, Jose M Porcel, Bruce W Robinson, Georgios T Stathopoulos, Ioannis Psallidas, Ioannis Kalomenidis, Jose M Porcel, Bruce W Robinson, Georgios T Stathopoulos

Abstract

Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

Provenance: Submitted article, peer reviewed.

Copyright ©ERS 2016.

References

    1. Rahman NM, Ali NJ, Brown G, et al. . Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: Suppl 2, ii54–ii60.
    1. Clive AO, Bhatnagar R, Psallidas I, et al. . Individualised management of malignant pleural effusion. Lancet Respir Med 2015; 3: 505–506.
    1. Mongardon N, Pinton-Gonnet C, Szekely B, et al. . Assessment of chronic pain after thoracotomy: a 1-year prevalence study. Clin J Pain 2011; 27: 677–681.
    1. Roberts ME, Neville E, Berrisford RG, et al. . Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: Suppl 2, ii32–ii40.
    1. Antony VB, Loddenkemper R, Astoul P, et al. . Management of malignant pleural effusions. Eur Respir J 2001; 18: 402–419.
    1. Clive AO, Kahan BC, Hooper CE, et al. . Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69: 1098–1104.
    1. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med 2012; 186: 487–492.
    1. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 2009; 64: 139–143.
    1. Davies HE, Mishra EK, Kahan BC, et al. . Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. Jama 2012; 307: 2383–2389.
    1. Rahman NM, Pepperell J, Rehal S, et al. . Effect of opioids versus NSAIDs and larger versus smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. Jama 2015; 314: 2641–2653.
    1. Meyer PC. Metastatic carcinoma of the pleura. Thorax 1966; 21: 437–443.
    1. Rodriguez-Panadero F, Borderas Naranjo F, Lopez Mejias J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989; 2: 366–369.
    1. Antony VB. Immunological mechanisms in pleural disease. Eur Respir J 2003; 21: 539–544.
    1. Heath RM, Jayne DG, O'Leary R, et al. . Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004; 90: 1437–1442.
    1. Rehnberg J, Zendehrokh N, Dejmek A. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions. Anal Quant Cytol Histol 2007; 29: 217–220.
    1. van der Wal BC, Hofland LJ, Marquet RL, et al. . Paracrine interactions between mesothelial and colon-carcinoma cells in a rat model. Int J Cancer 1997; 73: 885–890.
    1. Chen YM, Yang WK, Whang-Peng J, et al. . Elevation of interleukin-10 levels in malignant pleural effusion. Chest 1996; 110: 433–436.
    1. Li R, Ruttinger D, Li R, et al. . Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbecks Arch Surg 2003; 388: 406–412.
    1. Oshikawa K, Yanagisawa K, Tominaga S, et al. . Expression and function of the ST2 gene in a murine model of allergic airway inflammation.Clin Exp Allergy 2002; 32: 1520–1526.
    1. Ye ZJ, Zhou Q, Yin W, et al. . Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett 2012; 326: 23–32.
    1. Ye ZJ, Zhou Q, Yuan ML, et al. . Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy. Am J Respir Crit Care Med 2012; 185: 660–669.
    1. Prado-Garcia H, Aguilar-Cazares D, Flores-Vergara H, et al. . Effector, memory and naive CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 2005; 47: 361–371.
    1. Scherpereel A, Grigoriu BD, Noppen M, et al. . Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer 2013; 13: 324.
    1. Pace E, Di Sano C, Ferraro M, et al. . Altered CD94/NKG2A and perforin expression reduce the cytotoxic activity in malignant pleural effusions. Eur J Cancer 2011; 47: 296–304.
    1. Yanagawa E, Uchida A, Moore M, et al. . Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients. Cancer Immunol Immunother 1985; 19: 163–167.
    1. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J 1997; 10: 1701–1702.
    1. Jongsma J, van Montfort E, Vooijs M, et al. . A conditional mouse model for malignant mesothelioma. Cancer Cell 2008; 13: 261–271.
    1. Stathopoulos GT, Zhu Z, Everhart MB, et al. . Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006; 34: 142–150.
    1. Yeh HH, Lai WW, Chen HH, et al. . Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006; 25: 4300–4309.
    1. Psallidas I, Stathopoulos GT, Maniatis NA, et al. . Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene 2013; 32: 528–535.
    1. Stathopoulos GT, Kollintza A, Moschos C, et al. . Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 2007; 67: 9825–9834.
    1. Stathopoulos GT, Psallidas I, Moustaki A, et al. . A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008; 100: 1464–1476.
    1. Yano S, Shinohara H, Herbst RS, et al. . Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157: 1893–1903.
    1. Giannou AD, Marazioti A, Spella M, et al. . Mast cells mediate malignant pleural effusion formation. J Clin Invest 2015; 125: 2317–2334.
    1. Stathopoulos GT, Sherrill TP, Karabela SP, et al. . Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med 2010; 182: 1273–1281.
    1. Ma X, Yao Y, Yuan D, et al. . Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PloS One 2012; 7: e53449.
    1. Moschos C, Psallidas I, Cottin T, et al. . A sulindac analogue is effective against malignant pleural effusion in mice. Lung Cancer 2011; 73: 171–175.
    1. Moschos C, Psallidas I, Kollintza A, et al. . The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia 2009; 11: 298–304.
    1. Psallidas I, Karabela SP, Moschos C, et al. . Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer 2010; 9: 56.
    1. Stathopoulos GT, Moschos C, Loutrari H, et al. . Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008; 178: 50–59.
    1. Gordon CE, Feller-Kopman D, Balk EM, et al. . Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med 2010; 170: 332–339.
    1. Havelock T, Teoh R, Laws D, et al. . Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: Suppl 2, ii61–ii76.
    1. Bugalho A, Ferreira D, Dias SS, et al. . The diagnostic value of transthoracic ultrasonographic features in predicting malignancy in undiagnosed pleural effusions: a prospective observational study. Respiration 2014; 87: 270–278.
    1. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990; 154: 487–492.
    1. Hallifax RJ, Haris M, Corcoran JP, et al. . Role of CT in assessing pleural malignancy prior to thoracoscopy. Thorax 2014.
    1. Porcel JM, Hernandez P, Martinez-Alonso M, et al. . Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest 2015; 147: 502–512.
    1. Hooper C, Lee YC, Maskell N, et al. . Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: Suppl 2, ii4–ii17.
    1. Renshaw AA, Dean BR, Antman KH, et al. . The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997; 111: 106–109.
    1. van Zandwijk N, Clarke C, Henderson D, et al. . Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis 2013; 5: E254–E307.
    1. Scherpereel A, Astoul P, Baas P, et al. . Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479–495.
    1. Segal A, Sterrett GF, Frost FA, et al. . A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013; 45: 44–48.
    1. Henderson DW, Reid G, Kao SC, et al. . Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013; 66: 847–853.
    1. Maskell NA, Gleeson FV, Davies RJO. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003; 361: 1326–1330.
    1. Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991; 114: 271–276.
    1. Hallifax RJ, Corcoran JP, Ahmed A, et al. . Physician-based ultrasound-guided biopsy for diagnosing pleural disease. Chest 2014; 146: 1001–1006.
    1. Creaney J, Dick IM, Robinson BW. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr Opin Pulm Med 2015; 21: 352–356.
    1. Pass HI, Lott D, Lonardo F, et al. . Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564–1573.
    1. Porcel JM, Vives M, Esquerda A, et al. . Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004; 126: 1757–1763.
    1. Creaney J, Yeoman D, Demelker Y, et al. . Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008; 3: 851–857.
    1. Pass HI, Levin SM, Harbut MR, et al. . Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417–1427.
    1. Tsai TH, Su KY, Wu SG, et al. . RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J 2012; 39: 677–684.
    1. Robinson BW, Creaney J, Lake R, et al. . Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612–1616.
    1. Creaney J, Segal A, Olsen N, et al. . Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. Dis Markers 2014; 2014: 413946.
    1. Sriram KB, Relan V, Clarke BE, et al. . Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology 2011; 7: 737–752.
    1. Blyth KG. Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax 2015; 70: 374.
    1. Mejer J, Mortensen KM, Hansen HH. Mepacrine hydrochloride in the treatment of malignant pleural effusion. A controlled randomized trial. Scand J Respir Dis 1977; 58: 319–323.
    1. Martinez-Moragon E, Aparicio J, Sanchis J, et al. . Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65: 108–113.
    1. Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 2013; 19: 374–379.
    1. Feller-Kopman D, Berkowitz D, Boiselle P, et al. . Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84: 1656–1661.
    1. Agarwal R, Paul AS, Aggarwal AN, et al. . A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis. Respirology 2011; 16: 1064–1069.
    1. Kishi K, Homma S, Sakamoto S, et al. . Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. Eur Respir J 2004; 24: 263–266.
    1. Ren S, Terman DS, Bohach G, et al. . Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004; 126: 1529–1539.
    1. Ukale V, Agrenius V, Hillerdal G, et al. . Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. Lung Cancer 2004; 43: 323–328.
    1. Thomas R, Francis R, Davies HE, et al. . Interventional therapies for malignant pleural effusions: the present and the future. Respirology 2014; 19: 809–822.
    1. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; CD002916.
    1. Dresler CM, Olak J, Herndon JE II, et al. . Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909–915.
    1. Rintoul RC, Ritchie AJ, Edwards JG, et al. . Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 2014; 384: 1118–1127.
    1. Janssen JP, Collier G, Astoul P, et al. . Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535–1539.
    1. Maskell NA, Lee YC, Gleeson FV, et al. . Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377–382.
    1. Terra RM, Junqueira JJ, Teixeira LR, et al. . Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest 2009; 136: 361–368.
    1. Yim AP, Chan AT, Lee TW, et al. . Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62: 1655–1658.
    1. Rahman NM, Davies HE, Salzberg M, et al. . Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. Lancet Oncol 2008; 9: 946–952.
    1. Xia H, Wang XJ, Zhou Q, et al. . Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PloS One 2014; 9: e87060.
    1. Bhatnagar R, Laskawiec-Szkonter M, Piotrowska HE, et al. . Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open 2014; 4: e007045.
    1. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med 2011; 26: 70–76.
    1. Fysh ET, Tremblay A, Feller-Kopman D, et al. . Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest 2013; 144: 1597–1602.
    1. Bibby AC, Clive AO, Slade GC, et al. . Survival in patients with malignant pleural effusions who developed pleural infection: a retrospective case review from six UK centers. Chest 2015; 148: 235–241.
    1. Bhatnagar R, Kahan BC, Morley AJ, et al. . The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. Trials 2015; 16: 48.
    1. Bhatnagar R, Maskell N. Developing a ‘pleural team’ to run a reactive pleural service. Clin Med 2013; 13: 452–456.
    1. Basak SK, Veena MS, Oh S, et al. . The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PloS One 2009; 4: e5884.
    1. Macosko EZ, Basu A, Satija R, et al. . Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 2015; 161: 1202–1214.
    1. Thomas R, Cheah HM, Creaney J, et al. . Longitudinal measurement of pleural fluid biochemistry and cytokines in malignant pleural effusions. Chest 2016. [in press; DOI: 10.1016/j.chest.2016.01.001].
    1. Tsai TH, Wu SG, Chang YL, et al. . Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 2012; 7: 993–1000.
    1. Ost DE, Jimenez CA, Lei X, et al. . Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest 2014; 145: 1347–1356.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner